SAB BIOTHERAPEUTICS, INC.: income tax expense or benefit
Income tax expense or benefit for SAB BIOTHERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All SAB BIOTHERAPEUTICS, INC. financial histories
What this measure means
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
Exact concept: us-gaap:IncomeTaxExpenseBenefit. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 0 | USD | 2026-03-09 | 10-K · 0001833214-26-000003 |
| 2024-01-01 | 2024-12-31 | 0 | USD | 2026-03-09 | 10-K · 0001833214-26-000003 |
| 2023-01-01 | 2023-12-31 | 0 | USD | 2025-03-31 | 10-K · 0000950170-25-046994 |
| 2022-01-01 | 2022-12-31 | 25,629 | USD | 2024-03-29 | 10-K · 0000950170-24-038219 |
| 2021-01-01 | 2021-12-31 | 0 | USD | 2023-04-14 | 10-K · 0001437749-23-010343 |
| 2020-01-01 | 2020-12-31 | 0 | USD | 2022-03-29 | 10-K · 0000950170-22-004935 |
Related financial histories
- SAB BIOTHERAPEUTICS, INC.: total assets
- SAB BIOTHERAPEUTICS, INC.: total liabilities
- SAB BIOTHERAPEUTICS, INC.: stockholders equity
- SAB BIOTHERAPEUTICS, INC.: cash and cash equivalents
- SAB BIOTHERAPEUTICS, INC.: net income or loss
- SAB BIOTHERAPEUTICS, INC.: operating cash flow
- SAB BIOTHERAPEUTICS, INC.: capital expenditure payments
- SAB BIOTHERAPEUTICS, INC.: contract revenue excluding tax
- SAB BIOTHERAPEUTICS, INC.: financing cash flow
- SAB BIOTHERAPEUTICS, INC.: investing cash flow
- SAB BIOTHERAPEUTICS, INC.: retained earnings or deficit
- SAB BIOTHERAPEUTICS, INC.: basic weighted-average shares
- SAB BIOTHERAPEUTICS, INC.: diluted weighted-average shares
- SAB BIOTHERAPEUTICS, INC.: basic earnings per share
- SAB BIOTHERAPEUTICS, INC.: diluted earnings per share
- SAB BIOTHERAPEUTICS, INC.: net property, plant and equipment
- SAB BIOTHERAPEUTICS, INC.: share-based compensation expense
- SAB BIOTHERAPEUTICS, INC.: operating income or loss
- SAB BIOTHERAPEUTICS, INC.: current assets
- SAB BIOTHERAPEUTICS, INC.: interest expense
- SAB BIOTHERAPEUTICS, INC.: current liabilities
- SAB BIOTHERAPEUTICS, INC.: current accounts payable
- SAB BIOTHERAPEUTICS, INC.: net current accounts receivable
- SAB BIOTHERAPEUTICS, INC.: operating expenses
- SAB BIOTHERAPEUTICS, INC.: research and development expense
Inspect the source
- Entity
- SAB BIOTHERAPEUTICS, INC. / CIK 0001833214
- Captured
- 2026-09-21T17:30:30.932Z
- SEC response SHA-256
77a9d5e74034d5680bee440489a5722f0205b7102ec23dd33e3ff98bbc2065ac
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001833214.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))